Overview: Next-generation sequencing (NGS) is the massively parallel sequencing technology that has revolutionized the biological sciences. With its ultra-high throughput, scalability, and speed, NGS enables researchers to perform a wide variety of applications and study biological systems at a level never before possible. Illumina, Pacific Biosciences of California, Thermo Fisher scientific and Oxford Nanopore technology offers next-generation sequencing instruments based on different technologies such as Reversible terminator sequencing, Sequencing by ligation, Single-molecule, real-time sequencing (SMRT), ion semiconductor sequencing technology and Nanopore sequencing technology respectively. Wide range of diagnostic applications, continuous technology advancements are making it more efficient and user-friendly, but the complications associated with data storage and lack of skilled professional are some of the factors which may hamper growth to an extent.
Market Analysis: The “Global Next-Generation Sequencing market” is estimated to witness a CAGR of 18.6% during the forecast period 2018–2024. The global market is analyzed based on five segments – Technology, Products, Application, End-users and regions.
For Further Details about this Market Visit The Press Release@ https://www.trendsmarketresearch.com/report/sample/9896
Regional Analysis: The regions covered in the report are the North America, Europe, Asia Pacific, and Rest of the World (ROW). North America is the major shareholder in the global next-generation sequencing market, followed by Europe. Asia-Pacific region is expected to grow at high CAGR during the forecasted period due to increasing funding for healthcare research, growing patient pool, and increasing healthcare expenditure. The markets in emerging counties such as, India, China and Brazil are expected to grow at a rapid pace for next five years.
Technology Analysis: The next-generation sequencing market by technology is segmented into reversible terminator sequencing, ion semiconductor sequencing, sequencing by ligation, single molecule real-time sequencing, nanopore sequencing and others. Reversible terminator sequencing occupied a major market share in 2017 and is expected to remain same during the forecasted period.
Product Analysis: The market by product type is segmented into instruments, consumables and reagents and services. The services segment of the NGS market includes data analysis services and sequencing services. Among various application, consumables and reagents occupied the largest share in 2017, due to increased usage and need of consumables throughout the sample preparation, library construction, and various other pre-requisite steps of next-generation sequencing.
Application Analysis: The market by application is segmented into diagnostics, biomarker discovery, drug discovery, agriculture and animal research and others. Diagnostics includes prenatal testing, cancer diagnostics, genetic screening, pre-implantation, HLA typing and various other clinical diagnostics applications. The diagnostics application occupied a major share in 2017, due to increasing usage of next-generation sequencing for disease diagnosis.
Request For Report Discount@ https://www.trendsmarketresearch.com/report/discount/9896
End-Users Analysis: The market by end-users is segmented into academic and research institutes, hospitals and clinics, biotech and pharma companies and others. Among various end-users of the NGS market, academic and research institutes occupied a major share in 2017.
Key Players: Illumina, Inc., Thermo Fisher Scientific, Inc., Pacific Biosciences of California, Oxford Nanopore Technologies Limited, Beijing Genomics Institute, Agilent Technologies, Inc., Qiagen N.V., Eurofins Scientific, F. Hoffmann-La Roche, DNASTAR, Inc., Biomatters Limited and other predominate and niche players.
The increase in prevalence of cancer among population across the globe and the increase in biomarkers adoption in tumor profiling are factors escalating the growth of cancer tumor profiling market.Cancer is generally differentiated as uncontrolled cell growth which could be fatal.
The cell mutation leads to abnormal cell growth which affects the neighboring cells and organs.
It also helps in determining the specific therapeutics for the patient.Get Sample Copy of report Click on the link @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cancer-tumor-profiling-marketCancer Tumor Profiling Market Scope and Market SizeThe global cancer tumor profiling market is segmented on the basis of cancer type, biomarker type, technology, technique and application.
The growth amongst these segments will help you analyze meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
On the basis of cancer type, the cancer tumor profiling market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma cancer and other cancer.On the basis of biomarker type, the cancer tumor profiling market is segmented into genomic biomarker and protein biomarker.On the basis of technology, the cancer tumor profiling market is segmented into immunoassays, next-generation sequencing, polymerase chain reaction, mass spectrometry, in-situ hybridization, microarrays and others.On the basis of technique, the cancer tumor profiling market is segmented into genomics, proteomics, metabolomics and epigenetics.On the basis of application, the cancer tumor profiling market is segmented into research, biomarker discovery, personalized medicine, clinical application, diagnostics, prognostics, screening and treatment and monitoring.Get Full Table of Contents with Charts, Figures & Tables @ https://www.databridgemarketresearch.com/toc/?dbmr=global-cancer-tumor-profiling-marketGlobal Cancer Tumor Profiling Market Country Level AnalysisGlobal cancer tumor profiling market is analyzed and market size insights and trends are provided by country, cancer type, biomarker type, technology, technique and application as referenced above.
The countries covered in the cancer tumor profiling market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.North America dominates the cancer tumor profiling market because of the increasing number of cancer/tumor patients, presence of leading players, rise in oncology research activities to novel therapy and advanced technologies and their growing adoption.
Factors such as the increasing R activities and expenditure in the life science industry, increasing funding for proteomics research and drug discovery, and the growing collaboration between industries and academic institutes are the key drivers of the research antibodies market.The Research Antibodies Market is projected to reach USD 14.1 billion by 2025 from USD 10.1 billion in 2020, at a CAGR of 6.7% during the forecast period.
Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=94212793Market Segmentation:-On the basis of product, the reagents segment accounted for the largest share of the global research antibodies market (including reagents), in 2016.
This can be attributed to the fact that a large number of reagents are used in various routine assays and techniques.Based on technology, the western blotting segment accounted for the largest share of the Research Reagents Market.
Its ability to quantify as little as 0.1 nanograms of protein in a sample with high specificity makes it an indispensable tool in proteomic research; this is the key factor driving market growth.Based on application, the proteomics segment accounted for the largest share of the Research Reagents Market.
The large share of this segment is attributed to the deployment of proteomic-based approaches in biomarker detection and cancer profiling, increasing R expenditure, and availability of funds from various organizations.Based on end user, the pharmaceutical & biotechnological companies segment accounted for the largest share of the Research Antibodies and Reagents Market owing to the high uptake of research-specific antibodies in the drug discovery and development process, along with the increasing use of these research tools in the ever-developing proteomics research sector.Key Market Opportunities: - 1 High Growth Opportunities in Emerging Markets 2 Increasing Demand for Personalized Medicine and Protein Therapeutics 3 Growths in Stem Cell and Neurobiology Research 4 Increasing Focus on Biomarker DiscoveryRegional Analysis:-North America accounted for the largest share of the Research Antibodies and Reagents Market in 2016, followed by Europe.
This regional segment shows significant market growth opportunities owing to the increasing research activities in the fields of proteomics and genomics, favorable government funding initiatives, and the growing focus of stakeholders on research projects.Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=94212793Top Key Players:-The major players in the research antibodies market (including reagents) are Thermo Fisher Scientific, Inc. (U.S.), Merck Group (Germany), Abcam plc (U.K.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Cell Signaling Technology, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), GenScript (U.S.), PerkinElmer, Inc. (U.S.), Lonza (Switzerland), and BioLegend, Inc. (U.S.).
The increasing focus on biomarker discovery and toxicogenomics, along with the increasing interest in outsourcing services, is expected to offer significant growth opportunities for the players operating in the global RNA analysis/transcriptomics market.
On the other hand, the requirement of high capital investments and data management issues are expected to restrain the growth of this market to a certain extent.The growth of this market is majorly driven by the increasing demand for personalized medicine, increasing pharmaceutical and biotechnology R expenditure and government funding for omics, and the increasing applications of RNA sequencing in the transcriptomics market.Personalized medicine, which has become a core area of research in the healthcare industry, has entered mainstream clinical practice and is changing how many diseases are identified, classified, and treated.These advancements are particularly evident in the area of oncology.
According to the Personalized Medicine Coalition report (2017), the number of personalized drugs, treatments, and diagnostic products has increased since 2006, and this trend is expected to continue in the coming years.Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=240344576The microarray technology used in transcriptomic analysis offers the promise of widespread study of diseases at the genomic level.
It also aids in developing novel clinical biomarkers, identifying novel molecular abnormalities, and investigating drug efficacy.Moreover, RNA sequencing data from transcriptomics studies have low genome coverage and high amplification bias, which makes data analysis extremely challenging, especially without effective bioinformatics tools.
Many existing tools developed for bulk cell sequencing have not been effective in the analysis of transcriptomics data.The PCR segment accounted for the largest share of the RNA analysis/transcriptomics market in 2019.
PCR is the most suitable technique for interrogating a relatively small number of transcripts in a large set of samples.
The study involved four major activities in estimating the current size of the global non-invasive prenatal testing market.
The next step was to validate these findings, assumptions, and sizing values with industry experts across the value chain through primary research.
Both top-down and bottom-up approaches were employed to estimate the complete market size.According to a new market research report “Non-Invasive Prenatal Testing (NIPT) Market by Instruments (Ultrasound, NGS, PCR, Microarray), Consumables, Method (FCMB, cf-DNA), Application (Trisomy, Microdeletion, Genetics, Rh factor) & End User (Hospital, Diagnostic Labs) – Global Forecast to 2021″, published by MarketsandMarkets, The global NIPT market is expected to reach USD 2.88 Billion by 2021 from USD 1.35 Billion in 2016, at a CAGR of 16.4% during the forecast period.Growth in this market is driven by the high risk of chromosomal abnormalities with increasing maternal age, growing preference for non-invasive techniques over invasive methods, improving reimbursement scenario for NIPT, and increasing awareness of NIPT.
However, a dearth of skilled professionals is restraining the growth of this market.Browse in-depth TOC on “Non-Invasive Prenatal Testing (NIPT) Market”110 tables48 figures150 pagesDownload PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=145607690The major factors driving the growth of this market include the growing preference for non-invasive techniques over invasive methods, rising focus on reimbursement for NIPT, launch of new and advanced NIPT products, and increasing maternal age (associated with growth in the risk of chromosomal abnormalities in babies).
Furthermore, untapped emerging markets are expected to offer potential growth opportunities to players operating in the NIPT market during the forecast period.The Non-Invasive Prenatal Testing Market is segmented based on product, method, application, end user, and region.
Factors such as high risk of chromosomal disorders with increasing maternal age and rising government investments are driving the growth of the NIPT market in this region.
To order this 290+ page report, which features 50+ figures and 100+ tables, please visit this link Key Market Insights Over 200 players situated across the globe, claim to offer a variety of services for proteome profiling, and have developed the required expertise to process different sample typesThe market is fragmented, featuring the presence of both industry and non-industry players that are involved in providing proteome profiling services for various applicationsThe current landscape includes a mix of both established players and new entrants; close to 40% of the companies offering proteome profiling services were established over the last two decadesSeveral contract service providers, involved in this domain, are steadily expanding their capabilities in order to enhance their respective proteome profiling service portfolio and maintain a competitive edge in the industryThe growing trend of outsourcing proteome profiling operations is evident form the rise in recent partnership activity; the maximum number of collaborations were observed to have been inked in 2019The benefits of proteome profiling service presently outweigh the challenges related to their existing capabilities; the growing optimism in this domain is evident in the opinions of industry veteransThe market is anticipated to grow at CAGR of 15%, till 2030, and the projected opportunity is likely to be distributed across various type of applications, sponsors and key geographical regions For more information, please visit https://www.rootsanalysis.com/reports/proteome-profiling-services.html Table of Contents PREFACE 1.1.
Recent Developments and Future Outlook 5.3.
Recent Developments and Future Outlook COMPANY PROFILES: PROTEOME PROFILING SERVICE PROVIDERS IN ASIA PACIFIC AND REST OF THE WORLD7.1.
Recent Developments and Future Outlook COMPANY COMPETITIVENESS ANALYSIS8.1.
Proteome Profiling Services Market, 2020-2030: Geographical Distribution12.3.4.
Proteome Profiling Services Market in Rest of the World, 2020-2030 IMPACT OF THE COVID-19 PANDEMIC ON PROTEOME PROFILING SERVICES MARKET13.1.
Antibiotics Market The global antibiotics market is expected to reach USD 40.78 billion by 2025.
Global antibiotics market report presents thorough competitive analysis along with the market Size, share, and Future scope.
This study also analyzes the opportunities, market drivers, and challenges.Request sample copy of this report at: https://www.adroitmarketresearch.com/contacts/request-sample/1282Major players in the global antibiotics market are Abbott Laboratories, Merck & Co. Inc., GlaxoSmithKline Plc, F.Hoffmann-La Roche Ltd., Mylan N.V., Sanofi, Pfizer Inc., Novartis International AG, and Cipla Ltd among others.Adroit Market Research report on global antibiotics market gives a quantitative narration of the market demand, trends, drivers, restraints and opportunities spanning from 2015 to 2025.
Additionally, the market has been assessed based on Porter's five forces analysis, along with the depiction of the industry’s value chain.
Many low and middle income countries face both antibiotics excess and access issues.
A 2015 study by the Centers for Disease Dynamics and Control found that global antibiotic consumption had increased by 65% in the past 15 years (from 21.1 billion to 34.8 billion defined daily doses).
